DarioHealth (DRIO) Stock Price, News & Analysis

Company Overview

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

Key Stats

• Today's Range: $0.87 to $0.95
• 50-Day Range: $0.78 to $1.45
• 52-Week Range: $0.68 to $3.49
• Volume: 76,216 shs
• Average Volume: 118,813 shs
• Market Capitalization: $26.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Buy

DarioHealth Stock Analysis - MarketRank™

DarioHealth scored higher than 48% of companies evaluated by MarketBeat, and ranked 596th out of 1,014 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

DarioHealth has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

DarioHealth has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for DarioHealth are expected to grow in the coming year, from ($1.21) to ($1.04) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of DarioHealth is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of DarioHealth is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

DarioHealth has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.02% of the outstanding shares of DarioHealth have been sold short.

Short Interest Ratio / Days to Cover

DarioHealth has a short interest ratio ("days to cover") of 19.2, which indicates bearish sentiment.

Change versus previous month

Short interest in DarioHealth has recently increased by 11.11%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DarioHealth does not currently pay a dividend.

Dividend Growth

DarioHealth does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.02% of the outstanding shares of DarioHealth have been sold short.

Short Interest Ratio / Days to Cover

DarioHealth has a short interest ratio ("days to cover") of 19.2, which indicates bearish sentiment.

Change versus previous month

Short interest in DarioHealth has recently increased by 11.11%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.53

News Sentiment

DarioHealth has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for DarioHealth this week, compared to 1 article on an average week.

Search Interest

Only 3 people have searched for DRIO on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added DarioHealth to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, DarioHealth insiders have bought more of their company's stock than they have sold. Specifically, they have bought $16,500.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

15.70% of the stock of DarioHealth is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 33.39% of the stock of DarioHealth is held by institutions.

DRIO Stock Analysis - Frequently Asked Questions

How have DRIO shares performed this year?

DarioHealth's stock was trading at $1.72 at the beginning of 2024. Since then, DRIO shares have decreased by 49.2% and is now trading at $0.8740.
View the best growth stocks for 2024 here.

How were DarioHealth's earnings last quarter?

DarioHealth Corp. (NASDAQ:DRIO) released its earnings results on Thursday, August, 8th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.51) by $0.43. The firm had revenue of $6.26 million for the quarter, compared to analysts' expectations of $7.57 million. DarioHealth had a negative trailing twelve-month return on equity of 74.64% and a negative net margin of 265.33%.

Does DarioHealth have any subsidiaries?

The following companies are subsidiaries of DarioHealth: PsyInnovations Inc., Upright Technologies Ltd., Labstyle Innovation Ltd., PsyInnovations India Private Limited., and Upright Technologies Inc..

Who are DarioHealth's major shareholders?

Top institutional shareholders of DarioHealth include Nantahala Capital Management LLC (7.99%), Appian Way Asset Management LP (4.60%) and Y.D. More Investments Ltd (3.28%). Insiders that own company stock include Erez Raphael, Steven Charles Nelson, Oded Cohen and Dror Bacher.
View institutional ownership trends.

How do I buy shares of DarioHealth?

Shares of DRIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of DarioHealth own?

Based on aggregate information from My MarketBeat watchlists, some other companies that DarioHealth investors own include Aeterna Zentaris (AEZS), Vascular Biogenics (VBLT), Nano Dimension (NNDM), Pluristem Therapeutics (PSTI), NVIDIA (NVDA) and AbbVie (ABBV).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 9/18/2024
• Next Earnings (Estimated): 11/07/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:DRIO
• CUSIP: N/A
• CIK: 1533998
• Web: www.mydario.com
• Phone: (833) 914-3796
• Fax: 972-4770-4059
• Employees: 200
• Year Founded: 2011

Price Target and Rating

• Average Stock Price Target: $4.00
• High Stock Price Target: $4.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +357.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.68)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-59,430,000.00
• Net Margins: -265.33%
• Pretax Margin: -275.41%
• Return on Equity: -74.64%
• Return on Assets: -43.99%

Debt

• Debt-to-Equity Ratio: 0.34
• Current Ratio: 2.26
• Quick Ratio: 1.96

Sales & Book Value

• Annual Sales: $19.15 million
• Price / Sales: 1.37
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.14 per share
• Price / Book: 0.41

Miscellaneous

• Outstanding Shares: 29,923,000
• Free Float: 25,225,000
• Market Cap: $26.15 million
• Optionable: Optionable
• Beta: 1.46